https://scholars.lib.ntu.edu.tw/handle/123456789/568469
標題: | Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up | 作者: | Yu M.-L. Lee C.-M CHI-LING CHEN Chuang W.-L Lu S.-N CHEN-HUA LIU Wu S.-S Liao L.-Y Kuo H.-T Chao Y.-C Tung S.-Y Yang S.-S JIA-HORNG KAO Su W.-W Lin C.-L HUNG-CHIH YANG PEI-JER CHEN DING-SHINN CHEN CHUN-JEN LIU |
公開日期: | 2013 | 出版社: | John Wiley and Sons Inc. | 卷: | 57 | 期: | 6 | 起(迄)頁: | 2135-2142 | 來源出版物: | Hepatology | 摘要: | Patients dually infected with hepatitis C virus (HCV)/hepatitis B virus (HBV) have a higher risk of developing advanced liver disease or hepatocellular carcinoma compared with monoinfected patients. Yet, there is a similar rate of sustained virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy in these patients compared with HCV-monoinfected patients and a high hepatitis B surface antigen (HBsAg) seroclearance rate. The durability of hepatitis C and B clearance in coinfected patients was investigated in a 5-year follow-up study. Patients with active HCV genotype 1, both HBV-coinfected (n = 97) and HBV-monoinfected (n = 110), underwent 48-week combination therapy with peginterferon alfa-2a plus ribavirin. In patients with active HCV genotype 2 or 3, both HBV-coinfected (n = 64) and monoinfected (n = 50) patients underwent 24-week combination therapy. A total of 295 (91.9%) patients completed treatment and 24 weeks posttreatment follow-up; 264 (89.5%) patients agreed to receive additional follow-up for up to 5 years after the end of treatment. After a median follow-up of 4.6 ± 1.0 years, six of the 232 patients achieving SVR developed HCV RNA reappearance, including five HCV genotype 1/HBV-coinfected patients and one HCV genotype 2/3-monoinfected patient. Subgenomic analysis of the HCV core gene indicated that five patients developed delayed recurrence of HCV infection. Overall, the cumulative recurrence rate of HCV infection was 2.3% (0.4%/year; 95% confidence interval [CI], 0.9%-5.5%). The cumulative HBsAg seroclearance rate was 30.0% (95% CI, 21.5%-42.0%); with 33.1% (95% CI, 21.8%-50.1%) in the 48-week combination therapy group and 24.3% (95% CI, 13.7%-42.9%) in the 24-week therapy group. Conclusion: Peginterferon alfa-2a and ribavirin therapy provides good HCV SVR durability and a high accumulative HBsAg seroclearance rate in patients who are coinfected with HCV and HBV. ? 2013 American Association for the Study of Liver Diseases. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984578350&doi=10.1002%2fhep.26266&partnerID=40&md5=5a8c2d438db278e4030a8228fe3fcedf https://scholars.lib.ntu.edu.tw/handle/123456789/568469 |
ISSN: | 0270-9139 | DOI: | 10.1002/hep.26266 | SDG/關鍵字: | hepatitis B surface antigen; peginterferon alpha2a; peginterferon alpha2a plus ribavirin; robatrol; unclassified drug; virus RNA; adult; antiviral therapy; article; concurrent infection; controlled clinical trial; controlled study; drug efficacy; female; follow up; genome analysis; genotype; hepatitis B; hepatitis C; Hepatitis C virus; human; major clinical study; male; multicenter study; outcome assessment; priority journal; recurrence risk; recurrent disease; serology; treatment duration; viral clearance; virus core; virus gene |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。